Newsroom
Sorted by: Latest
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Law Offices of Frank R. Cruz Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire About Securities Fraud Class Action...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Momentum UCITS ETF 20.08.2026 FTMO.LN IE000CY30YV9 3,100,002.00 USD 95,549,476.36 30.822 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 20.08.2026 SDVI.LN IE000YVOQ2A3 40,361.00 USD 1,195,653.08 29.624 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 20.08.2026 SDVY.LN IE0001R850E1 15,804,007.00 USD 413,151,003.17 26.142 ...
-
SharkNinja Conjures Ninja SLUSHi Twist x Practical Magic 2 Collection
NEEDHAM, Mass.--(BUSINESS WIRE)--SharkNinja Inc. (NYSE: SN), a global product design and technology company, is launching four Ninja® SLUSHi® Twist x Practical Magic 2 colorways in custom packaging to celebrate the film's September 10, 2026, release in theaters. In the sequel, the original Ninja SLUSHi helps the Owens sisters reinvent their legendary "Midnight Margaritas." To celebrate the partnership, Ninja is bringing that moment beyond the screen, reimagining the iconic scene and giving fans...
-
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced it has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from its apitegromab Biologics License Application (BLA) for the treatment of spinal muscular atrophy (SMA) in...